Scientists investigate DCAMKL-1 in pancreatic tumors
NCT ID NCT01580241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a protein called DCAMKL-1, which may be a stem cell marker in pancreatic cancer. Researchers want to see how its levels change before and after treatment in 60 patients. The goal is to understand how current therapies affect this marker, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stephensen Cancer Center
Oklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?